Proactive Investors - Run By Investors For Investors

Eli Lilly and Co unveils cheaper version of popular insulin injection Humalog

Mark Emalfarb, CEO of the biopharmaceutical group Dyadic, calls the move 'a very good first step'
diabetes logo and sugar
The half-priced version of Humalog is called insulin Lispro

Eli Lilly and Co (NYSE:LLY) has unveiled a cheaper generic version of Humalog, its insulin injection, in a bid to cut prices for diabetics.

The half-priced version of Humalog is called insulin Lispro and has the same molecule as the more expensive product, which generates annual sales of $3 billion. It will be available in vial and pen options.

A single vial will cost $137.35 while a five-pack of KwikPens will be $265.20.

“The significant rebates we pay on insulin do not directly benefit all patients. This needs to change,” said David Ricks, Lilly’s CEO. “For people with diabetes, a lower-priced insulin can serve as a bridge that addresses gaps in the system until a more sustainable model is achieved.”

READ: Fitbit shares soar on news of diabetes monitoring feature on its new smartwatch

Humalog can still be purchased via standard insurance plans. But vials and pens of the cheaper insulin have been manufactured and Lilly is now looking to make them available in pharmacies as “quickly as possible.”

Mark Emalfarb, CEO of biopharmaceutical company Dyadic International Inc (OTCMKTS:DYAI), called the move “a very good first step” in what is likely to be a “long and drawn out process of making biologics more accessible and affordable” to patients.

In an email to Proactive, Emalfarb cautioned that cutting profit margins isn’t the “final solution” to “dramatically lowering the cost” of bio-manufacturing expensive biologic drugs.

Eli Lilly shares were flat at $127.26 in afternoon trade Tuesday.

Contact Ellen Kelleher at [email protected]

View full DYAI profile View Profile

Dyadic International Inc Timeline

Related Articles

patch
Wed
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
scientist at petrie dish
Wed
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use